Corporate GovernanceMay 15, 2026, 05:32 PM
RenovoRx Remediates Internal Control Weaknesses in 2025 10-K/A
AI Summary
RenovoRx, Inc. filed an amendment to its 2025 Form 10-K to revise risk factor disclosures related to previously identified material weaknesses in internal control over financial reporting. The company announced that these material weaknesses were remediated as of December 31, 2025, and management confirmed the effectiveness of its internal control over financial reporting. Despite this improvement in controls, RenovoRx continues to face significant financial challenges, including substantial net losses and the ongoing need for additional capital to fund its development and commercialization efforts.
Key Highlights
- Material weaknesses in internal control over financial reporting were remediated by December 31, 2025.
- Management assessed internal control over financial reporting as effective as of December 31, 2025.
- The company reported an accumulated deficit of approximately $61.4 million as of December 31, 2025.
- Net losses for fiscal year 2025 were approximately $11.2 million, up from $8.8 million in 2024.
- Revenue from RenovoCath commercial sales reached approximately $1.1 million for the year ended December 31, 2025.
- Cash and cash equivalents were approximately $13.0 million as of March 23, 2026.
Price Impact
More from RNXT